Keywords
Treatment
Infections
SLE
How to Cite
Abstract
Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune and multisystemic inflammatory disease, with varied clinical presentations, with joint and skin involvement being the most common, and is most frequent in young and middle-aged women. Objective: This article aims to summarize and present current data and considerations about SLE, with a broader approach to its various treatments. Methods: Researches were made on Medline, Scielo and LILACS databases. Articles written in English, Spanish or Portuguese and published since 2016 were considered for this study. Those articles not related to the proposed theme and/or published before 2016 weren't considered. Furthermore, review articles were not used for the results. Results: Those analyzed articles pointed SLE as a disease influenced by environmental and genetic factors, but its etiology is not clearly understood. As for treatments, the need to control the immune response is evident and this achievement depends on the effectiveness of the medication, patient´s response and what adverse effects they endure. Among those analyzed treatments, the results are promising and it is necessary to individually evaluate the application of each one. Conclusion: It is important to highlight the relevance of different treatments, choosing the best one for each type of patient. However, more studies are needed to fully comprehend the condition of SLE and improve patient management and treatment.
References
Illescas‐Montes, Rebeca, et al. “Infectious Processes and Systemic Lupus Erythematosus.” Immunology, vol. 158, no. 3, 30 Aug. 2019, pp. 153–160, 10.1111/imm.13103.
Rivas-Larrauri, Francisco, and Marco Antonio Yamazaki-Nakashimada. “Systemic Lupus Erythematosus: Is It One Disease?” Reumatología Clínica (English Edition), vol. 12, no. 5, Sept. 2016, pp. 274–281, 10.1016/j.reumae.2016.01.002. Acesso em 13 Junho 2022.
Trentin, Francesca, et al. “One Year in Review 2021: Systemic Lupus Erythematosus.” Clinical and Experimental Rheumatology, vol. 39, no. 2, 1 Mar. 2021, pp. 231–241, pubmed.ncbi.nlm.nih.gov/33843578/. Acesso em 13 Junho 2022.
Oku, Kenji, and Tatsuya Atsumi. “Systemic Lupus Erythematosus: Nothing Stale Her Infinite Variety.” Modern Rheumatology, vol. 28, no. 5, 3 Sept. 2018, pp. 758–765, 10.1080/14397595.2018.1494239. Acesso em 13 Junho 2022.
Ali, Asad, et al. “Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management.” Cureus, vol. 10, no. 9, 11 Sept. 2018, 10.7759/cureus.3288.
Fava, Andrea, and Michelle Petri. “Systemic Lupus Erythematosus: Diagnosis and Clinical Management.” Journal of Autoimmunity, vol. 96, Jan. 2019, pp. 1–13, 10.1016/j.jaut.2018.11.001.
Costi, Luisa Ribeiro, et al. “Mortalidade Por Lúpus Eritematoso Sistêmico No Brasil: Avaliação Das Causas de Acordo Com O Banco de Dados de Saúde Do Governo.” Revista Brasileira de Reumatologia, vol. 57, no. 6, Nov. 2017, pp. 574–582, 10.1016/j.rbr.2017.05.007.
Chen, L. Y., et al. “Systemic Lupus Erythematosus with and without a Family History: A Meta-Analysis.” Lupus, vol. 27, no. 5, 1 Apr. 2018, pp. 716–721, pubmed.ncbi.nlm.nih.gov/29087262/, 10.1177/0961203317739133. Acesso em 13 Junho 2022.
Yin, Xianyong, et al. “Meta-Analysis of 208370 East Asians Identifies 113 Susceptibility Loci for Systemic Lupus Erythematosus.” Annals of the Rheumatic Diseases, vol. 80, no. 5, 3 Dez. 2020, pp. 632–640, 10.1136/annrheumdis-2020-219209. Acesso em 13 Junho 2022.
Lima, Patrícia dos Santos, et al. “O Lúpus Eritematoso Sistêmico E Seu Processo de Adoecimento: Uma Concepção Feminina.” Revista Eletrônica Acervo Saúde, vol. 18, no. e115, 18 Dec. 2018, 10.25248/reas.e115.2019. Acesso em 13 Junho 2022.
Morand, Eric F., et al. “Trial of Anifrolumab in Active Systemic Lupus Erythematosus.” New England Journal of Medicine, vol. 382, no. 3, 16 Jan. 2020, pp. 211–221, 10.1056/nejmoa1912196. Acesso em 13 Junho 2022.
Chatham, W. Winn, et al. “Long‐Term Safety and Efficacy of Anifrolumab in Adults with Systemic Lupus Erythematosus: Results of a Phase 2 Open‐Label Extension Study.” Arthritis & Rheumatology, vol. 73, no. 5, 22 Nov. 2020, 10.1002/art.41598. Acesso em 13 Junho 2022.
Wallace, Daniel J, et al. “Baricitinib for Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial.” The Lancet, vol. 392, no. 10143, Jul. 2018, pp. 222–231, 10.1016/s0140-6736(18)31363-1. Acesso em 13 de Junho 2022.
He J, Zhang R, Shao M, et al. “Efficacy and safety of low-dose IL-2 in the treatment of systemic lúpus erythematosus: a randomised, double-blind, placebo-controlled trial.” Clinical Science, vol. 79, Set. 2019, pp141-149. 10.1136. Acesso em 13 de Junho 2022.
Brunner, Hermine I, et al. “Safety and Efficacy of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: Results from a Randomised, Placebo-Controlled Trial.” Annals of the Rheumatic Diseases, vol. 79, no. 10, 22 July 2020, pp. 1340–1348, 10.1136/annrheumdis-2020-217101. Acesso em 13 Junho 2022.
Zucchi, D. et al. “One year in review 2019: systemic lúpus erythematosus.” Clinical and experimental Rheumatology, vol 37, 1 Jul 2019, pp. 715-722. Acesso em 13 Junho 2022.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 João Vítor Giovannini Sad Ribeiro, João Vitor Jatobá Barbosa, Jordana de Castro Honorato, Júlia Brunetti Teles de Melo, Laura Drummond de Moura Miguez